Sumioka I, Matsura T, Kasuga S, Itakura Y, Yamada K
Institute for OTC Research, Wakunaga Pharmaceutical Co., Ltd., Hiroshima, Japan.
Jpn J Pharmacol. 1998 Oct;78(2):199-207. doi: 10.1254/jjp.78.199.
S-Allylmercaptocysteine (SAMC), one of the water-soluble organosulfur compounds in ethanol extracts of garlic (Allium sativum L.), has been shown to protect mice against acetaminophen (APAP)-induced liver injury. In this study, we examined the mechanisms underlying this hepatoprotection. SAMC (100 mg/kg, p.o.) given 2 and 24 hr before APAP administration (500 mg/kg, p.o.) suppressed the plasma alanine aminotransferase activity increases 3 to 12 hr after APAP administration significantly. The hepatic reduced glutathione levels of vehicle-pretreated mice decreased 1 to 6 hr after APAP administration, but SAMC pretreatment suppressed the reductions 1 to 6 hr after APAP administration significantly. These inhibitory effects of SAMC were dose-dependent (50-200 mg/kg) 6 hr after APAP administration. As SAMC pretreatment (50-200 mg/kg) suppressed hepatic cytochrome P450 2E1-dependent N-nitrosodimethylamine demethylase activity significantly in a dose-dependent manner, we suggest that one of its protective mechanisms is inhibition of cytochrome P450 2E1 activity. SAMC pretreatment also suppressed the increase in hepatic lipid peroxidation and the decrease in hepatic reduced coenzyme Q9 (CoQ9H2) levels 6 hr after APAP administration. The hepatic CoQ9H2 content of the SAMC pretreatment group was maintained at the normal level. Therefore, we suggest that another hepatoprotective mechanism of SAMC may be attributable to its antioxidant activity.
S-烯丙基巯基半胱氨酸(SAMC)是大蒜(葱属植物)乙醇提取物中的水溶性有机硫化合物之一,已被证明可保护小鼠免受对乙酰氨基酚(APAP)诱导的肝损伤。在本研究中,我们研究了这种肝脏保护作用的潜在机制。在给予APAP(500 mg/kg,口服)前2小时和24小时给予SAMC(100 mg/kg,口服),可显著抑制APAP给药后3至12小时血浆丙氨酸转氨酶活性的升高。给予APAP后1至6小时,溶剂预处理小鼠的肝脏还原型谷胱甘肽水平降低,但SAMC预处理可显著抑制给予APAP后1至6小时的降低。APAP给药后6小时,SAMC的这些抑制作用呈剂量依赖性(50-200 mg/kg)。由于SAMC预处理(50-200 mg/kg)以剂量依赖性方式显著抑制肝细胞色素P450 2E1依赖性N-亚硝基二甲胺脱甲基酶活性,我们认为其保护机制之一是抑制细胞色素P450 2E1活性。SAMC预处理还可抑制APAP给药后6小时肝脏脂质过氧化的增加和肝脏还原型辅酶Q9(CoQ9H2)水平的降低。SAMC预处理组的肝脏CoQ9H2含量维持在正常水平。因此,我们认为SAMC的另一种肝脏保护机制可能归因于其抗氧化活性。